Company / Free Cash Flow
Protalix BioTherapeutics, Inc. Free Cash Flow History
FY2015-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Free Cash Flow
-$2.5M
FY2025
5-year range
-$26.8M / -$2.5M
FY2021-FY2025
Trend
+90.4%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Free Cash Flow has fluctuated over the past 10 years, ranging from -$33M in FY2015 to -$2M in FY2025.
Based on SEC 10-K filings.
-$2M in FY2025.
Improved from -$12M to -$2M over the past 2 years.
Free Cash Flow over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2025, free cash flow increased 90.4% year-over-year.
- Lowest free cash flow in the period was in FY2015.
Company context
Key Data Points
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Free Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$2.5M | +90.4% |
| FY2024 | -$25.6M | -118.2% |
| FY2023 | -$11.7M | +56.1% |
| FY2022 | -$26.8M | -33.9% |
| FY2021 | -$20.0M | -137.1% |
| FY2020 | -$8.4M | +23.1% |
| FY2019 | -$11.0M | +55.7% |
| FY2017 | -$24.7M | +17.7% |
| FY2016 | -$30.1M | +7.6% |
| FY2015 | -$32.5M | -2171.0% |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026